ArticleFrontiers in microbiology2026
Assessment of 16S rRNA sequencing for analysis of circulating microbial DNA in colorectal cancer patients-proof of concept and early changes during experimental chemoimmunotherapy.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Circulating microbial DNA (cmDNA) is an emerging biomarker in cancer, yet its analytical and clinical utility remains to be validated. Methods: This study establishes a proof-of-concept for cmDNA sequencing and analysis using 16S rRNA amplicons in colorectal cancer (CRC) patient samples. Two cohorts were analyzed - the Test cohort ( Results: Both plasma and serum were suitable for cmDNA profiling; however, plasma was preferred due to higher numbers of bacterial reads and lower proportion of unassigned reads. Compared to METIMMOX patients with long-lasting treatment response, exhibiting a stable initial cmDNA composition, the patients unresponsive to chemoimmunotherapy showed an increase in alpha diversity (observed amplicon sequence variants: Conclusion: This study demonstrates the feasibility of cmDNA sequencing in CRC patients and highlights its potential to uncover treatment-related microbial shifts that may serve as non-invasive biomarkers of therapeutic response or resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.